Zaqlix Biopharm

Zaqlix Biopharm Awarded SBIR Grant from National Eye Institute

Zaqlix Biopharm Awarded SBIR Grant from National Eye Institute

San Antonio, TX July 31, 2014 — Zaqlix Biopharm (formerly America Stem Cell, Inc.) a clinical- stage biopharmaceutical company developing enzyme technologies and products to improve efficacy outcomes for cancer immunotherapy and cell therapy, announced today the receipt of an SBIR award to fund its program for a novel cell-based restorative approach to treat diabetes- related retinopathy. This SBIR award is from the National Eye Institute and Zaqlix Biopharm will be collaborating with Dr. Maria Grant from the Department of Ophthalmology at Indiana University School of Medicine to conduct the research.

Retinal vascular […]

Zaqlix Biopharm Appoints Christopher Calhoun to Business Advisory Board

Zaqlix Biopharm Appoints Christopher Calhoun to Business Advisory Board

San Diego, CA  June 3, 2014  — Zaqlix Biopharm (formerly America Stem Cell, Inc. or the “Company”), a clinical-stage biopharmaceutical company developing enzyme platform technologies/products  to improve efficacy outcomes for cell therapy and cancer immunotherapy,  announced today that it has appointed Christopher Calhoun to its Business Advisory Board.

Chris Calhoun is a co-founder of Cytori Therapeutics. He has served as its Vice-Chairman/Director and Chief Executive Officer.

Lynnet Koh, Chairman & CEO of  Zaqlix Biopharm, stated “Mr. Calhoun is a visionary entrepreuneur, a proven public company CEO with a successful track record with major […]

Zaqlix Biopharm Appoints Dr. Mark W. Schwartz to Board of Directors

San Antonio, TX   March 4, 2014  — Zaqlix Biopharm (formerly America Stem Cell, Inc., the “Company”) announced today that is has appointed Mark W. Schwartz, Ph.D. to the Company’s Board of Directors. Dr. Schwartz will serve the Company as an independent member of the Board.    As an independent director, Dr. Schwartz will assist in the Company in further enhancing its corporate governance protocols and oversight committees, as well as assist management in setting and meeting corporate goals, including establishing key strategic partnerships and providing guidance on long-term capital raising in both private and public markets.  With the appointment of […]

Zaqlix Biopharm Selected to Present at 2014 BIO CEO & Investor Conference

San Antonio, TX   February 5, 2014  — Zaqlix Biopharm (formerly America Stem Cell, Inc.) has been selected to present at the 2014 BIO CEO & Investor Conference being held in New York City on February 10-11, 2014.  The BIO CEO & Investor Conference is the largest investor conference focused on established and emerging publicly traded and select private biotech companies. Zaqlix Biopharm is a privately held clinical-stage biopharmaceutical company developing and commercializing breakthrough products designed to improve outcomes for patients receiving cell therapy.  Zaqlix Biopharm will be presenting in the oncology track for private companies to some of the most influential […]

America Stem Cell, Inc to Present at 12th Annual BIO Investor Forum. BIO Investor Forum to be held October 8-9 in San Francisco, Calif.

San Francisco, CA, October 1, 2013 – America Stem Cell, Inc (ASC) announced that Lynnet Koh, CEO will be presenting at the 12th Annual BIO Investor Forum. Hosted by the Biotechnology Industry Organization (BIO), the 12th Annual BIO Investor Forum features leading private and emerging public companies. The meeting will take place October 8-9 at the Palace Hotel in San Francisco, Calif.

“ASC was founded with the vision to make stem cell transplantation and cell therapy safer and more efficacious for patients. The profound efficacy and safety results from our current Phase I/IIa trial at M.D. Anderson Cancer Center with […]

AMERICA STEM CELL, INC. RECEIVES FDA CLEARANCE FOR ITS MULTI-CENTER NATIONWIDE TRIAL

AMERICA STEM CELL, INC. RECEIVES FDA CLEARANCE FOR ITS MULTI-CENTER NATIONWIDE TRIAL

San Antonio, TX  SEPTEMBER 4, 2012. America Stem Cell, Inc. (ASC) announced today it has received clearance from FDA for its Phase I/IIa nationwide multi-center dual-umbilical cord transplantation study evaluating ASC-101 in in patients with hematologic malignancies and myelodysplastic syndrome.

ASC-101 is currently undergoing evaluation in a single-center study at The University of Texas MD Anderson Cancer.  To date, 12 patients have been enrolled in the study with 9 patients evaluable.  On the basis of data obtained in the single-center study, FDA has given approval to proceed with a […]

AMERICA STEM CELL, INC. initiates a Phase I/II trial of ASC-101 in patients with hematologic malignancies undergoing dual-cord transplantation

AMERICA STEM CELL, INC. initiates a Phase I/II trial of ASC-101 in patients with hematologic malignancies undergoing dual-cord transplantation

Novel enzyme technology to enhance stem cell homing and engraftment for improved clinical outcomes for cancer patients

San Antonio, TX, August 27, 2012. America Stem Cell, Inc. announced today the initiation of a single-center study at The University of Texas MD Anderson Cancer Center evaluating ASC-101 in dual-umbilical cord transplantation in patients with hematologic malignancies.

“There is a significant unmet medical need to improve stem cell engraftment into bone marrow for patients undergoing umbilical cord transplantation, and America Stem Cell is committed to […]